NASDAQ:XENE

Xenon Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XENE

*Your capital is at risk

$53.46

+1.16 (+2.22%)

At Close: Jun 03, 2026

Xenon Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -60.52. In total, the insiders bought 2.47M and sold 412.02K XENE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-60.52
● Buy	2.47M shares
● Sell	412.02K shares
75% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Mar 09, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -60.52. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 02, 2026 Sell	Common Shares S-Sale	Mortimer Ian President & CEO	CEO / President	37 938 Value: $1.68M
Jan 02, 2026 Buy	Common Shares M-Exempt	Mortimer Ian President & CEO	CEO / President	40 000 Value: $299.6K
Dec 08, 2025 Sell	Common Shares S-Sale	Mortimer Ian President & CEO	CEO / President	8 820 Value: $402.1K
Dec 08, 2025 Sell	Common Shares S-Sale	Mortimer Ian President & CEO	CEO / President	2 010 Value: $93.1K
Dec 05, 2025 Sell	Common Shares S-Sale	Mortimer Ian President & CEO	CEO / President	14 375 Value: $647.3K
Nov 28, 2025 Sell	Common Shares S-Sale	Mortimer Ian President & CEO	CEO / President	97 Value: $4K
Oct 15, 2025 Buy	Share Option (Right to Buy) A-Award	Kelly Thomas Patrick Chief Financial Officer	C-Suite Officer	225 000 Value: $9.43M
Oct 15, 2025 Buy	Restricted Share Units A-Award	Kelly Thomas Patrick Chief Financial Officer	C-Suite Officer	30 000 Value: $1.26M
Oct 15, 2025 Buy	No securities are beneficially owned.	Kelly Thomas Patrick Chief Financial Officer	C-Suite Officer	0 Value: $0
Oct 01, 2025 Buy	Common Shares M-Exempt	Mortimer Ian President, CEO & Interim CFO	CEO / President	25 000 Value: $192.3K
Oct 01, 2025 Sell	Common Shares S-Sale	Mortimer Ian President, CEO & Interim CFO	CEO / President	25 000 Value: $1.00M
Oct 01, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Mortimer Ian President, CEO & Interim CFO	CEO / President	25 000 Value: $192.3K
Oct 01, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Mortimer Ian President, CEO & Interim CFO	CEO / President	25 000 Value: $192.3K
Oct 01, 2025 Sell	Common Shares S-Sale	Mortimer Ian President, CEO & Interim CFO	CEO / President	25 000 Value: $1.00M
Oct 01, 2025 Buy	Common Shares M-Exempt	Mortimer Ian President, CEO & Interim CFO	CEO / President	25 000 Value: $192.3K
Jun 23, 2025 Buy	Share Option (Right to Buy) A-Award	Cline Darren S Chief Commercial Officer	Officer	185 800 Value: $5.85M
Jun 23, 2025 Buy	No securities are beneficially owned.	Cline Darren S Chief Commercial Officer	Officer	0 Value: $0
Jun 23, 2025 Buy	No securities are beneficially owned.	Cline Darren S Chief Commercial Officer	Officer	0 Value: $0
Jun 23, 2025 Buy	Share Option (Right to Buy) A-Award	Cline Darren S Chief Commercial Officer	Officer	185 800 Value: $5.85M
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Patou Gary Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Patou Gary Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Machado Patrick Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Machado Patrick Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Gover Justin D. Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Gover Justin D. Director	Director	2 645 Value: $81.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XENON PHARMACEUTICALS INC.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...

Read Full Profile Here